TrialJAMA oncology2018

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

Pedro N Aguiar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.